Guggenheim Capital LLC Cuts Stake in AstraZeneca plc (AZN)

Guggenheim Capital LLC decreased its stake in shares of AstraZeneca plc (NYSE:AZN) by 14.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 149,720 shares of the company’s stock after selling 25,577 shares during the period. Guggenheim Capital LLC’s holdings in AstraZeneca were worth $5,196,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in AZN. Commerce Bank boosted its stake in AstraZeneca by 14.7% during the fourth quarter. Commerce Bank now owns 11,548 shares of the company’s stock worth $400,000 after acquiring an additional 1,480 shares in the last quarter. M&T Bank Corp boosted its stake in AstraZeneca by 0.5% during the fourth quarter. M&T Bank Corp now owns 317,119 shares of the company’s stock worth $11,003,000 after acquiring an additional 1,676 shares in the last quarter. TIAA FSB boosted its stake in AstraZeneca by 6.7% during the fourth quarter. TIAA FSB now owns 27,087 shares of the company’s stock worth $940,000 after acquiring an additional 1,692 shares in the last quarter. First Allied Advisory Services Inc. boosted its stake in AstraZeneca by 7.6% during the fourth quarter. First Allied Advisory Services Inc. now owns 23,845 shares of the company’s stock worth $825,000 after acquiring an additional 1,694 shares in the last quarter. Finally, Logan Capital Management Inc. boosted its stake in AstraZeneca by 7.0% during the fourth quarter. Logan Capital Management Inc. now owns 26,040 shares of the company’s stock worth $904,000 after acquiring an additional 1,710 shares in the last quarter. 15.14% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Shares of NYSE AZN opened at $34.97 on Monday. The company has a market capitalization of $88,575.38, a PE ratio of 8.17, a PEG ratio of 1.81 and a beta of 0.62. AstraZeneca plc has a 52-week low of $28.43 and a 52-week high of $36.70. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.62 and a current ratio of 0.80.

AstraZeneca (NYSE:AZN) last issued its earnings results on Friday, February 2nd. The company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.86. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The firm had revenue of $5.78 billion for the quarter, compared to the consensus estimate of $5.49 billion. During the same quarter in the prior year, the firm posted $1.21 earnings per share. The business’s revenue was up 3.4% on a year-over-year basis. research analysts anticipate that AstraZeneca plc will post 1.7 earnings per share for the current year.

The business also recently disclosed a semiannual dividend, which was paid on Monday, March 19th. Stockholders of record on Friday, February 16th were issued a dividend of $0.95 per share. The ex-dividend date was Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s payout ratio is 32.01%.

Several research firms recently commented on AZN. BMO Capital Markets set a $40.00 price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Thursday, March 22nd. Leerink Swann boosted their price objective on shares of AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 6th. Sanford C. Bernstein boosted their price objective on shares of AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. ValuEngine lowered shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 7th. Finally, Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. AstraZeneca has an average rating of “Hold” and an average price target of $36.32.

TRADEMARK VIOLATION WARNING: This article was originally published by WKRB News and is the property of of WKRB News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.wkrb13.com/2018/04/02/guggenheim-capital-llc-cuts-stake-in-astrazeneca-plc-azn.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply